The definitions of survival terms in OShnscc
Survival terms	Endpoint Event	Endpoint Time	Reference
OS (Overall Survival)	OS event, 1 for patient who was death from any cause, 0 for alive.	OS.time: last_contact_days_to or death_days_to, whichever is larger.	Liu, J., Lichtenberg, T., Hoadley, K. A. et al. (2018). An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell,173(2), 400-416.
DSS (Disease-Specific Survival)	DSS event, 1 for patient whose vital_status was Dead and tumor_status was WITH TUMOR. If a patient died from the disease shown in field of cause_of_death, the status of DSS would be 1 for the patient. 0 for patient whose vital_status was Alive or whose vital_status was Dead and tumor_status was TUMOR FREE. This is not a 100% accurate definition but is the best we could do with this dataset. Technically a patient could be with tumor but died of a car accident and therefore incorrectly considered as an event.	DSS.time: last_contact_days_to or death_days_to, whichever is larger.	Liu, J., Lichtenberg, T., Hoadley, K. A. et al. (2018). An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell,173(2), 400-416.
DFI (Disease-Free Interval)	DFI event, 1 for patient having new tumor event whether it is a local recurrence, distant metastasis, new primary tumor of the cancer, including cases with a new tumor event whose type is N/A. Disease free was defined by: first, treatment_outcome_first_course is "Complete Remission/Response"; if the tumor type doesn't have "treatment_outcome_first_course" then disease-free was defined by the value "R0" in the field of "residual_tumor"; otherwise, disease-free was defined by the value "negative" in the field of "margin_status". If the tumor type did not have any of these fields, then its DFI was NA. 0 for censored otherwise. New primary tumor in other organ was censored; patients who were Dead with tumor without new tumor event are excluded; patients wih stage IV are excluded too.	DFI.time: new_tumor_event_dx_days_to for events, or for censored cases, either last_contact_days_to or death_days_to, whichever is applicable.	Liu, J., Lichtenberg, T., Hoadley, K. A. et al. (2018). An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell,173(2), 400-416.
PFI (Progression-Free Interval)	PFI event, 1 for patient having new tumor event whether it was a progression of disease, local recurrence, distant metastasis, new primary tumors all sites , or died with the cancer without new tumor event, including cases with a new tumor event whose type is N/A. 0 for censored otherwise.	PFI.time: for events, either new_tumor_event_dx_days_to or death_days_to, whichever is applicable; or for censored cases, either last_contact_days_to or death_days_to, whichever is applicable.	Liu, J., Lichtenberg, T., Hoadley, K. A. et al. (2018). An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell,173(2), 400-416.
DFS (Disease-Free survival, also known as RFS)	DFS event, 1 for patient was measured relapse or death (from any cause) after primary treatment for a cancer ends that the patient survives without any signs or symptoms of that cancer; 0 for censored patients who was alive and in Complete Remission/Response when follow-up.	for events, time from the date of Complete Remission/Response until the date of relapse or death (from any cause) ; or for censored cases, time to last follow-up.	Bhatnagar B, Eisfeld AK, Kohlschmidt J, et al. Clinical and molecular characterization of patients with acute myeloid leukemia and sole trisomies of chromosomes 4, 8, 11, 13 or 21. Leukemia. 2020;34(2):358-368.
PFS (Progression -Free survival)	PFS event, 1 for patient was measured defined as definitive disease progression or death from any cause; 0 for censored otherwise.	for events, time from randomization to relapse or death from any cause, whichever occurred first; or for censored cases, time to last follow-up.	European Medicines Agency Appendix 1 to the guidelines on the evaluation of anticancer medicinal products in man: Methodological considerations for using Progression Free Survival (PFS) as primary endpoint in confirmatory trials for registration [Draft] 2006 Dec; www.emea.europa.eu/pdfs/human/ewp/ 26757506en.pdf.